BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ramucirumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ramucirumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03909334-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT03909334)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Osimertinib With and Without Ramucirumab in Locally Advanced or Meta
 static Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramucir
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03909334
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03527108-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT03527108)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Niv
 olumab Plus Ramucirumab in Patients With Recurrent\, Advanced\, Metastatic
  NSCLC\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03527108
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043427-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06043427)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: Paclitaxel and Ramucirumab +/- Z
 anidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06043427
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04205968-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT04205968)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: Ramucirumab and Paclitaxel or FO
 LFIRI in Advanced Small Bowel Cancers\nEstimated primary completion: 1 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramucirum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4205968
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT05999994)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: A Master Protocol (LY900023) Tha
 t Includes Several Clinical Trials of Drugs for Children and Young Adults 
 With Cancer\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05999994
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04999761-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ramucirumab: Phase 1 readout est. (NCT04999761)
DESCRIPTION:Ramucirumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: AB1
 22 Platform Study\nEstimated primary completion: June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04999761
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669740-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT07669740)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study on the 
 Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel
  in the Treatment of Gastric Cancer Patients With Short-term Recurrence Af
 ter Adjuvant Therapy\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07669740
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980000-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT05980000)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: Ramucirumab and Pembrolizumab vs
  Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell C
 arcinoma\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05980000
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT05642572)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 paring Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Can
 cer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)\nEstim
 ated primary completion: 30 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06448754)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Vol
 rustomig Priming Regimens Exploratory Phase II Platform Study\nEstimated p
 rimary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06251973)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study of agen
 T-797 in Combination With Botensilimab\, Balstilimab\, Ramucirumab\, and P
 aclitaxel for People With Esophageal\, Gastric\, or Gastro-esophageal Junc
 tion Cancer\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04069273-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270811
DTEND;VALUE=DATE:20270812
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT04069273)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: Novel SEQUEnced
  Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroe
 sophageaL Adenocarcinoma\nEstimated primary completion: 11 August 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04069273
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06038578-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06038578)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study of TRK-
 950 When Used in Combination With Ramucirumab and Paclitaxel in Patients W
 ith Gastric Cancer\nEstimated primary completion: 31 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06038578
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Ramucirumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivolu
 mab to Usual Treatment for People With Advanced Stomach or Esophageal Canc
 er\, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927857-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT05927857)
DESCRIPTION:Ramucirumab\, phase 1/2\, Gastric Cancer.\nStudy: Ramucirumab (
 Cyramza)\, Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Secon
 d Line Metastatic Gastric Cancer .\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramucirumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 27857
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Ramucirumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
 dding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With
  Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Plati
 num Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Ramucirumab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101 
 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Ramucirumab\, phase 1/2.\nStudy: Substudy 06D: Combination Ther
 apies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Key
 maker-U06)\nEstimated primary completion: 9 May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365581-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ramucirumab: Phase 1 readout est. (NCT05365581)
DESCRIPTION:Ramucirumab\, phase 1.\nStudy: A Study of ASP2138 Given by Itse
 lf or Given With Other Cancer Treatments in Adults With Stomach Cancer\, G
 astroesophageal Junction Cancer\, or Pancreatic Cancer\nEstimated primary 
 completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ramucirumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05365581
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031688-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06031688)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tar
 geted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exo
 n 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06031688
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06007937-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06007937)
DESCRIPTION:Ramucirumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Lorlatinib in Combination With Ramucirumab in People With Lung C
 ancer\nEstimated primary completion: 17 August 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06007937
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675136-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290114
DTEND;VALUE=DATE:20290115
SUMMARY:Ramucirumab: Phase 1 readout est. (NCT06675136)
DESCRIPTION:Ramucirumab\, phase 1\, Gastric Cancer.\nStudy: Nab-Paclitaxel 
 PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of 
 Stomach Cancer With Peritoneal Metastases\nEstimated primary completion: 1
 4 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramuc
 irumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06675136
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Ramucirumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 23 February 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ramucirumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nEstimate
 d primary completion: 6 April 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763171-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Ramucirumab: Phase 3 readout est. (NCT07763171)
DESCRIPTION:Ramucirumab\, phase 3.\nStudy: Paclitaxel\, Ramucirumab and Tis
 lelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score
  of 5 or More Advanced Gastroesophageal Adenocarcinoma\nEstimated primary 
 completion: September 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ramucirumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07763171
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962137-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06962137)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: Phase II RAINSP
 OT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esoph
 ageal Cancer\nEstimated primary completion: 31 December 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06962137
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546812-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT07546812)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: Study of Denikitug (GS-1811) Giv
 en Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastr
 ic\, Gastroesophageal Junction (GEJ)\, and Esophageal Adenocarcinomas\nEst
 imated primary completion: January 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07546812
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05719558-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Ramucirumab: Phase 1 readout est. (NCT05719558)
DESCRIPTION:Ramucirumab\, phase 1.\nStudy: A Study of ASP1002 in Adults for
  Treatment of Solid Tumors\nEstimated primary completion: 30 April 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05719558
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594548-2013@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300909
DTEND;VALUE=DATE:20300910
SUMMARY:Ramucirumab: Phase 1 readout est. (NCT07594548)
DESCRIPTION:Ramucirumab\, phase 1\, Gastric Cancer.\nStudy: Futibatinib Wit
 h Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unre
 sectable Gastric\, Gastroesophageal Junction\, or Esophageal Adenocarcinom
 a\nEstimated primary completion: 9 September 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07594548
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
